An FDA advisory panel voted on whether to recommend Galleri, the first multi-cancer blood screening test to reach that stage.
An AI-scored liquid biopsy from City of Hope caught stage 1 and 2 pancreatic cancer 87% of the time in…
Japanese bio-AI startup Craif banks $33M to push its urine-based pancreatic cancer test toward US launch.
Tempus AI adds Personalis' liquid biopsy and tumor sequencing capabilities in a $1.5 billion acquisition.